Key Updates
AbbVie rebounded +5.41% to $217.11 since the February 4 report, partially recovering from the post-earnings selloff but remaining down -4.98% YTD. The recovery follows Q4 2025 earnings that delivered a top-line beat with revenue of $16.62 billion (+10% YoY) and adjusted EPS of $2.71 versus consensus $2.65, while providing upbeat 2026 guidance of $14.37-$14.57 per share. However, the stock remains under pressure as the market digested mixed signals from the earnings report, particularly weakness in key growth driver Skyrizi which missed expectations despite strong absolute growth. The investment thesis remains intact with diversified immunology growth offsetting Humira erosion, though execution risk on newer products has increased following the earnings reaction.
Current Trend
AbbVie trades at $217.11, down -4.98% YTD and -3.79% over the past day, reflecting continued volatility following the February 4 earnings release. The stock has recovered +5.41% from the post-earnings low of $205.97 but remains well below the $228.72 pre-earnings level reached on February 2. Over the past six months, shares are up +10.10%, demonstrating medium-term strength despite recent weakness. The current price action suggests the market is reassessing valuation following the earnings miss on Skyrizi, though the stock has found support above $205 and is attempting to stabilize in the $215-220 range.
Investment Thesis
The investment thesis centers on AbbVie's successful navigation of the post-Humira era through a diversified immunology portfolio led by Skyrizi and Rinvoq, which delivered 32.5% and 29.5% growth respectively in Q4 2025. The company's immunology segment grew 18% to $8.63 billion in Q4, more than offsetting Humira's 26% decline. Strategic investments include the $650 million upfront payment for RC148 bispecific antibody rights with potential $4.95 billion in milestones, and the $175 million Arizona manufacturing facility acquisition to support next-generation delivery systems. The $100 billion U.S. investment commitment securing tariff exemptions and protection from future pricing mandates provides regulatory certainty through 2029.
Thesis Status
The thesis remains fundamentally intact but faces near-term execution challenges. The Q4 results validated the core premise of immunology-driven growth, with the segment delivering robust 18% expansion. However, according to Investor's Business Daily, "an unexpected suspect drove its beat," suggesting the earnings quality was questioned by the market. Reuters reported that shares fell despite upbeat 2026 profit forecasts due to a "key drug's sales miss," specifically Skyrizi's underperformance versus expectations. The 2026 guidance of $14.37-$14.57 per share exceeds consensus of $14.27, indicating management confidence, but the market's negative reaction suggests concerns about sustainable growth rates for the flagship immunology products. The Trump administration agreement provides medium-term regulatory stability, though the $100 billion investment commitment represents significant capital allocation that must deliver returns.
Key Drivers
Q4 2025 earnings delivered record net sales in only the second full year post-Humira LOE, with revenue of $16.62 billion (+10% YoY) beating consensus $16.41 billion. Net income reached $1.82 billion ($1.02 per share) versus a $22 million loss in the prior year, with adjusted EPS of $2.71 exceeding estimates of $2.65. The immunology portfolio grew 18% to $8.63 billion, driven by Skyrizi (+32.5%) and Rinvoq (+29.5%), though absolute Skyrizi sales missed analyst expectations according to Reuters. Bloomberg reported that Botox sales rebounded, contributing to the earnings beat and supporting the raised 2026 guidance. The RemeGen RC148 licensing agreement positions AbbVie in the high-growth bispecific antibody market with potential combination strategies for its ADC pipeline. The Trump administration three-year agreement provides tariff exemptions and protection from future pricing mandates in exchange for $100 billion in U.S. R&D and capital investments through 2036, offering regulatory certainty through the critical 2026-2029 period.
Technical Analysis
AbbVie is consolidating between $205-$230 following the post-earnings volatility. The stock found support at $205.97 on February 4, representing a -9.95% decline from the pre-earnings high of $228.72. The current price of $217.11 sits in the middle of this range, suggesting indecision as the market digests the earnings implications. The -4.98% YTD performance indicates weakness relative to the broader market, while the +10.10% six-month gain demonstrates the stock's previous momentum has stalled. Key resistance exists at $220-$225, with the $228-$230 pre-earnings level representing a significant technical hurdle. Support has been established at $205-$210, which must hold to maintain the medium-term uptrend. The -3.79% single-day decline reflects continued selling pressure, suggesting the recovery may be fragile without positive catalysts.
Bull Case
- Immunology portfolio delivering robust growth offsetting Humira decline: Q4 immunology segment grew 18% to $8.63 billion with Skyrizi up 32.5% and Rinvoq up 29.5%, demonstrating successful post-LOE transition strategy. Source
- 2026 guidance exceeds consensus with adjusted EPS of $14.37-$14.57: Management's upbeat forecast of $14.37-$14.57 per share tops analyst consensus of $14.27, indicating confidence in sustained growth trajectory. Source
- Trump administration agreement provides regulatory certainty through 2029: Three-year voluntary agreement secures tariff exemptions and protection from future pricing mandates, reducing regulatory risk during critical growth phase. Source
- Strategic RC148 bispecific antibody acquisition expands oncology pipeline: $650 million upfront payment with up to $4.95 billion in milestones for novel PD-1/VEGF bispecific antibody positions AbbVie in high-growth combination therapy market for solid tumors. Source
- Manufacturing expansion supports long-term capacity growth: $175 million Arizona facility acquisition and $100 billion U.S. investment commitment over next decade strengthens domestic manufacturing capabilities for next-generation immunology and neuroscience medicines. Source
Bear Case
- Skyrizi sales missed expectations despite strong absolute growth: Key growth driver Skyrizi underperformed analyst estimates in Q4 despite 32.5% YoY growth, raising concerns about sustainable growth rates and market penetration limits. Source
- Market reaction suggests earnings quality concerns: Stock declined -9.95% post-earnings despite beating estimates, with IBD noting "an unexpected suspect drove its beat," indicating investor skepticism about underlying performance drivers. Source
- Continued Humira erosion with 26% Q4 decline: Flagship product Humira sales fell 26% in Q4 2025 due to biosimilar competition, requiring sustained high growth from newer products to maintain overall revenue trajectory. Source
- Significant capital commitments may constrain financial flexibility: $100 billion U.S. investment commitment over next decade, combined with $650 million RC148 upfront payment and $175 million facility acquisition, represents substantial capital allocation requiring execution to generate returns. Source
- YTD underperformance signals weakening momentum: Down -4.98% YTD and trading -3.79% lower today, with stock failing to hold pre-earnings gains, suggesting deteriorating investor sentiment and potential for further downside if growth concerns persist. Source